Osteodystrofi ved kronisk leversygdom

Pia Eiken; Atheer Adel Al-Omran; Frank Vinholt Schiødt

doi:10.61409/V12230769

Osteodystrofi ved kronisk leversygdom

Pia Eiken^*
, Atheer Adel Al-Omran
, Frank Vinholt Schiødt

^*Corresponding author af dette arbejde

Medicinsk Afdeling

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Hepatic osteodystrophy is defined as a metabolic bone disease that may occur in individuals with chronic liver disease (CLD). Hepatic osteodystrophy commonly manifests with osteoporosis and fragility fractures. This review finds that patients older than 50 years with CLD should be screened for possible osteoporosis earlier if they experience fragility fractures. Treatment includes calcium, vitamin D, and lifestyle interventions. Bisphosphonates, such as alendronate, and denosumab increase bone mineral density in CLD patients.

Bidragets oversatte titel	Osteodystrophy in chronic liver disease
Originalsprog	Dansk
Artikelnummer	V12230769
Tidsskrift	Ugeskrift for laeger
Vol/bind	188
DOI	https://doi.org/10.61409/V12230769
Status	Udgivet, E-publikation før trykning - 8 jun. 2026

Emneord

Humans
Liver Diseases/complications
Osteoporosis/etiology
Chronic Disease
Bone Diseases, Metabolic/etiology
Bone Density Conservation Agents/therapeutic use
Vitamin D/therapeutic use
Bone Density/drug effects

Adgang til dokumentet

10.61409/V12230769

Citationsformater

@article{9fa9780977a64920a0affc0f5d5f8250,

title = "Osteodystrofi ved kronisk leversygdom",

abstract = "Hepatic osteodystrophy is defined as a metabolic bone disease that may occur in individuals with chronic liver disease (CLD). Hepatic osteodystrophy commonly manifests with osteoporosis and fragility fractures. This review finds that patients older than 50 years with CLD should be screened for possible osteoporosis earlier if they experience fragility fractures. Treatment includes calcium, vitamin D, and lifestyle interventions. Bisphosphonates, such as alendronate, and denosumab increase bone mineral density in CLD patients.",

keywords = "Humans, Liver Diseases/complications, Osteoporosis/etiology, Chronic Disease, Bone Diseases, Metabolic/etiology, Bone Density Conservation Agents/therapeutic use, Vitamin D/therapeutic use, Bone Density/drug effects",

author = "Pia Eiken and Al-Omran, \{Atheer Adel\} and Schi{\o}dt, \{Frank Vinholt\}",

note = "Published under Open Access CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2026",

month = jun,

day = "8",

doi = "10.61409/V12230769",

language = "Dansk",

volume = "188",

journal = "Ugeskrift for laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Osteodystrofi ved kronisk leversygdom

AU - Eiken, Pia

AU - Al-Omran, Atheer Adel

AU - Schiødt, Frank Vinholt

N1 - Published under Open Access CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2026/6/8

Y1 - 2026/6/8

N2 - Hepatic osteodystrophy is defined as a metabolic bone disease that may occur in individuals with chronic liver disease (CLD). Hepatic osteodystrophy commonly manifests with osteoporosis and fragility fractures. This review finds that patients older than 50 years with CLD should be screened for possible osteoporosis earlier if they experience fragility fractures. Treatment includes calcium, vitamin D, and lifestyle interventions. Bisphosphonates, such as alendronate, and denosumab increase bone mineral density in CLD patients.

AB - Hepatic osteodystrophy is defined as a metabolic bone disease that may occur in individuals with chronic liver disease (CLD). Hepatic osteodystrophy commonly manifests with osteoporosis and fragility fractures. This review finds that patients older than 50 years with CLD should be screened for possible osteoporosis earlier if they experience fragility fractures. Treatment includes calcium, vitamin D, and lifestyle interventions. Bisphosphonates, such as alendronate, and denosumab increase bone mineral density in CLD patients.

KW - Humans

KW - Liver Diseases/complications

KW - Osteoporosis/etiology

KW - Chronic Disease

KW - Bone Diseases, Metabolic/etiology

KW - Bone Density Conservation Agents/therapeutic use

KW - Vitamin D/therapeutic use

KW - Bone Density/drug effects

U2 - 10.61409/V12230769

DO - 10.61409/V12230769

M3 - Review

C2 - 42273844

SN - 0041-5782

VL - 188

JO - Ugeskrift for laeger

JF - Ugeskrift for laeger

M1 - V12230769

ER -

Osteodystrofi ved kronisk leversygdom

Abstract

Emneord

Adgang til dokumentet

Fingeraftryk

Citationsformater